Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

83 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma.
Clingan P, Ladwa R, Brungs D, Harris DL, McGrath M, Arnold S, Coward J, Fourie S, Kurochkin A, Malan DR, Mant A, Sharma V, Shue H, Tazbirkova A, Berciano-Guerrero MA, Charoentum C, Dalle S, Dechaphunkul A, Dudnichenko O, Koralewski P, Lugowska I, Montaudié H, Muñoz-Couselo E, Sriuranpong V, Oliviero J, Desai J. Clingan P, et al. Among authors: ladwa r. J Immunother Cancer. 2023 Oct;11(10):e007637. doi: 10.1136/jitc-2023-007637. J Immunother Cancer. 2023. PMID: 37848259 Free PMC article.
A phase 1, single centre, open label, escalating dose study to assess the safety, tolerability and immunogenicity of a therapeutic human papillomavirus (HPV) DNA vaccine (AMV002) for HPV-associated head and neck cancer (HNC).
Chandra J, Woo WP, Finlayson N, Liu HY, McGrath M, Ladwa R, Brauer M, Xu Y, Hanson S, Panizza B, Frazer IH, Porceddu SV. Chandra J, et al. Among authors: ladwa r. Cancer Immunol Immunother. 2021 Mar;70(3):743-753. doi: 10.1007/s00262-020-02720-7. Epub 2020 Sep 12. Cancer Immunol Immunother. 2021. PMID: 32918586 Free PMC article. Clinical Trial.
A phase Ib study to assess the safety of the human papillomavirus DNA vaccine (AMV002) in combination with durvalumab for HPV-associated oropharyngeal squamous cell carcinoma.
Ladwa R, Chandra J, Woo WP, Finlayson N, Liu H, McGrath M, See A, Hughes BG, Cooper CL, Jackson JE, Dzienis M, Xu Y, Panizza B, Frazer I, Porceddu SV. Ladwa R, et al. Front Oncol. 2024 Jul 5;14:1419258. doi: 10.3389/fonc.2024.1419258. eCollection 2024. Front Oncol. 2024. PMID: 39035738 Free PMC article.
83 results